Colony Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Colony Group’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$46K	–	809
2023 Q1	$46K	Buy	+25,000	New	+$31K	﹤0.01%	774
2022 Q4	–	Sell	-20,000	Closed	-$47K	–	900
2022 Q3	$47K	Hold	20,000	–	–	﹤0.01%	762
2022 Q2	$61K	Hold	20,000	–	–	﹤0.01%	803
2022 Q1	$136K	Hold	20,000	–	–	﹤0.01%	819
2021 Q4	$167K	Buy	20,000 +10,000	+100%	+$82.4K	﹤0.01%	782
2021 Q3	$74K	Hold	10,000	–	–	﹤0.01%	814
2021 Q2	$255K	Hold	10,000	–	–	0.01%	686
2021 Q1	$103K	Hold	10,000	–	–	﹤0.01%	747
2020 Q4	$70K	Hold	10,000	–	–	﹤0.01%	724
2020 Q3	$82K	Buy	+10,000	New	+$62K	﹤0.01%	708

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Colony Group's JNCE Position: Q2 2023 in Review

Colony Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 25,000 shares — an estimated $46K sold.

Colony Group first reported a position in JNCE in Q3 2020 and held it in 10 quarters. The position peaked at $255K in Q2 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Colony Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Colony Group sold 25,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $46K.
Colony Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
Colony Group's Jounce Therapeutics, Inc. Common Stock position peaked at $255K in Q2 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Colony Group's 13F filing for Q2 2023, filed 15 Aug 2023.